{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T12:59:19Z","timestamp":1781182759897,"version":"3.54.1"},"reference-count":49,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Chronic hepatitis B (CHB) refers to a global infectious disease caused by the hepatitis B virus. The treatment of CHB causes a heavy economic burden to society. To ensure the rational allocation of medical resources in the whole society and achieve the goal of patients' satisfaction and economy, this study aimed to evaluate the economics of de novo combination of tenofovir alafenamide fumarate (TAF) as the first\u2010line nucleos(t)ide analogues (NAs) and peginterferon alfa\u20102b (PEG\u2010IFN\u03b1\u20102b) versus PEG\u2010IFN\u03b1\u20102b monotherapy of HBeAg\u2010positive CHB in China. The Markov model was used to simulate the transition of HBeAg\u2010positive CHB patients aged 30 in China under various health states using TreeAge Pro 2011 software. The cycle length was 1\u2009year, and the cycle period of the model was 50\u2009years. The model parameters included clinical efficacy, cost, transition probability and discount rate. Cost\u2010effectiveness analysis was conducted through simulation of the total cost and quality adjusted life years (QALYs) of various treatment options through models. Simultaneously, one\u2010way sensitivity analysis, probabilistic sensitivity analysis and scenario analysis were performed. De novo combination of TAF and PEG\u2010IFN\u03b1\u20102b and PEG\u2010IFN\u03b1\u20102b monotherapy resulted in 11.16 and 10.81 QALYs, with total costs of $55559.72 and $57670.23, respectively. De novo combination strategy for HBeAg\u2010positive CHB patients can save costs and obtain more health outcomes. Sensitivity analyses showed the reliability of the results. From the perspective of the whole society, the de novo combination strategy of TAF and PEG\u2010IFN\u03b1\u20102b for patients with HBeAg\u2010positive CHB may be more cost\u2010effective than PEG\u2010IFN\u03b1\u20102b monotherapy.<\/jats:p>","DOI":"10.1111\/jvh.70170","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T08:47:23Z","timestamp":1775724443000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost\u2010Effectiveness of De Novo Combination of Tenofovir Alafenamide Fumarate and Peginterferon Alfa\u20102b Versus Peginterferon Alfa\u20102b Monotherapy of\n                    <scp>HBeAg<\/scp>\n                    \u2010Positive Chronic Hepatitis B in China"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5447-5525","authenticated-orcid":false,"given":"Na","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Pharmacy Fujian Medical University Union Hospital  Fuzhou People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maobai","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Fujian Medical University Union Hospital  Fuzhou People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfu","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Fujian Medical University Union Hospital  Fuzhou People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Fujian Medical University Union Hospital  Fuzhou People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Fujian Medical University Union Hospital  Fuzhou People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunmin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Fujian Medical University Union Hospital  Fuzhou People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Fujian Medical University Union Hospital  Fuzhou People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab241"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00124-8"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2211764"},{"key":"e_1_2_10_5_1","unstructured":"World Health Organization \u201cCombating Hepatitis B and C to Reach Elimination by 2030[EB\/ OL]. (2016\u201005\u201027) [2022\u201005\u201020] \u201dhttps:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/206453\/WHO_HIV_2016_5_27_eng.pdf."},{"issue":"6","key":"e_1_2_10_6_1","first-page":"443","article-title":"Changes in the Cytokine Profiles of Patients With Chronic Hepatitis B During Antiviral Therapy","volume":"34","author":"Li M.","year":"2021","journal-title":"Biomedical and Environmental Sciences"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13150"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000431"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0327298"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.06.024"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067975"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16162878"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1403805"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00139-9"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2018.1518423"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33949"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2005.03813.x"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-86555-1"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.36026"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.11.031"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2010.00782.x"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22884"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-007-5001-0"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2003.03187.x"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2016.15535"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-3023-5"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep42253"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000000445"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0313898"},{"key":"e_1_2_10_32_1","volume-title":"Fachinformation Vemlidy 25 mg Filmtabletten (Tenofovir Alafenamid)","author":"Gilead Sciences International Ltd","year":"2017"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-13-37"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12482"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00297.x"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-016-0486-8"},{"key":"e_1_2_10_37_1","first-page":"7","article-title":"China Guidelines for Pharmacoeconomic Evaluations (In Chinese)","volume":"3","author":"Pharmacoeconomics Committee of Chinese Pharmaceutical Association","year":"2011","journal-title":"Zhongguo Weisheng Jingji"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.knee.2021.02.004"},{"issue":"3","key":"e_1_2_10_39_1","first-page":"527","article-title":"How Many Monte Carlo Samples Are Needed for Probabilistic Cost\u2010Effectiveness Analyses[J]","volume":"11","author":"Yaesoubi R.","year":"2024","journal-title":"Value in Health"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105763"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2004.07.003"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2007.05.001"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.05.007"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.3138\/canlivj-2022-0043"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm-21-1666"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3019"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14801"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.11.020"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.05.032"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001584"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.70170","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.70170","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.70170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T12:18:35Z","timestamp":1781180315000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.70170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/jvh.70170"],"URL":"https:\/\/doi.org\/10.1111\/jvh.70170","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"2025-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70170"}}